Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Thermo Fisher Scientific to Divest Microbiology Business to Astorg for $1.075 Billion – Strategic Portfolio Optimization

Fineline Cube Apr 28, 2026
Company Deals

Aureka Biotechnologies Secures $35M Series A+ Financing to Advance AuraIDE Platform for Functional Antibody Design

Fineline Cube Apr 28, 2026
Company Deals

Hangzhou’s Adcoris Licenses First-in-Class 5T4-Targeting ADC ACR246 to U.S. Biotech K2 Therapeutics in Deal Worth Up to $730 Million

Fineline Cube Apr 27, 2026
Company Deals

Sino Biopharmaceutical’s Chia Tai Tianqing and Shanghai Reunion Partner to Commercialize Respacio Hydrogel for Cervical Cancer Radiotherapy Protection in China

Fineline Cube Apr 27, 2026
Company Deals

Beijing QL Biopharma Files HKEX IPO Prospectus with Diversified GLP-1 Portfolio Targeting Global Obesity and Metabolic Disease Markets

Fineline Cube Apr 27, 2026
Policy / Regulatory

NMPA Tightens Post-Marketing Requirements for Conditionally Approved Drugs in China, Mandating Four-Year Confirmatory Studies and Annual Progress Reporting

Fineline Cube Apr 27, 2026
Company Drug

Novartis Secures European Commission Approval for Rhapsido (remibrutinib) in Chronic Spontaneous Urticaria – Expanding Global BTK Inhibitor Franchise

Fineline Cube Apr 28, 2026
Company Drug

BeBetter Medicine Secures FDA Clearance for BEBT-701 Clinical Study – First-in-Class Dual-Target Therapy for Hypertension and High LDL-C

Fineline Cube Apr 28, 2026
Company Drug

Oricell Therapeutics’ GPRC5D-Targeted CAR-T Therapy Earns FDA Fast Track for Multiple Myeloma

Fineline Cube Jul 15, 2024

Oricell Therapeutics Co., Ltd, a leading biopharmaceutical company based in China, has announced that it...

Company Deals

Legend Biotech’s Shares Leap on Acquisition Rumors; Parent Genscript Biotech Corp. Follows Suit

Fineline Cube Jul 15, 2024

Chinese biopharmaceutical firm Legend Biotech (NASDAQ: LEGN), a specialist in chimeric antigen receptor (CAR) T-cell...

Company R&D

Oxford Study Clears Semaglutide of Neuro/Psychiatric Risks, Suggests Cognitive and Addiction Benefits

Fineline Cube Jul 15, 2024

Researchers at the prestigious Oxford University in the UK have unveiled groundbreaking real-world data on...

Company Drug

Simcere Pharmaceutical’s COVID-19 Therapy Xiannuoxin Earns Full Approval in China

Fineline Cube Jul 12, 2024

Simcere Pharmaceutical Group (HKG: 2096), a biopharmaceutical company based in China, has announced that its...

Company Deals R&D

Beijing Tsingke Biotech Partners with Zhejiang University’s Innovation Center for Nucleic Acid Drug Delivery

Fineline Cube Jul 12, 2024

Beijing Tsingke Biotech Co., Ltd., a prominent player in the DNA/RNA synthesis domain based in...

Company Drug

Jiangsu Hengrui’s Subsidiary Conducts First Surgical Dosing in Parkinson’s Gene Therapy Clinical Trial

Fineline Cube Jul 12, 2024

Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276), a leading pharmaceutical company in China, has announced...

Company Medical Device

Medtronic Launches Advanced Signia Stapler in China, Expanding Surgical Capabilities

Fineline Cube Jul 12, 2024

Medtronic (NYSE: MDT), the US-Irish medical device giant, has announced the launch of its intelligent...

Company Drug

Shanghai Escugen Initiates Phase III Clinical Trial for Breast Cancer Drug Candidate ESG401

Fineline Cube Jul 12, 2024

Shanghai Escugen, a biopharmaceutical company based in China, has announced the dosing of the first...

Company Deals

Ipsen Strikes Global Licensing Deal with Foreseen Biotechnology for First-in-Class ADC FS001

Fineline Cube Jul 12, 2024

Ipsen (EPA: IPN; OTCMKTS: IPSEY), a French biopharmaceutical company, has announced a global licensing agreement...

Company Drug

Eisai and Biogen’s Alzheimer’s Therapy Leqembi Receives Marketing Approval in Hong Kong

Fineline Cube Jul 12, 2024

Eisai Co., Ltd, a Japanese pharmaceutical company, along with its co-development partner Biogen Inc. (NASDAQ:...

Company Drug

Pfizer’s Once-Daily Danuglipron Selected for Full Clinical Development for Type 2 Diabetes and Obesity

Fineline Cube Jul 12, 2024

Pfizer Inc. (NSE: PFIZER), a leading pharmaceutical company in the U.S., has announced that a...

Company Drug

Novo Nordisk’s Awiqli Faces FDA Setback as BLA Draws Complete Response Letter

Fineline Cube Jul 12, 2024

Novo Nordisk A/S (NYSE: NVO) announced that the U.S. Food and Drug Administration issued a...

Company Drug

CSPC Pharmaceutical’s RSV mRNA Vaccine SYS6016 Receives Clinical Trial Approval from NMPA

Fineline Cube Jul 12, 2024

CSPC Pharmaceutical Group Ltd (HKG: 1093), a leading pharmaceutical company based in China, has announced...

Company Drug

Sichuan Biokin Pharmaceutical Gets NMPA Approval for BL-M14D1 Clinical Trial in Solid Tumors

Fineline Cube Jul 12, 2024

Sichuan Biokin Pharmaceutical Co., Ltd (SHA: 688506), a pharmaceutical company based in China, has announced...

Company Drug

Beijing Sun-Novo Gets NMPA Green Light for STC008 Clinical Trial in Tumor Cachexia

Fineline Cube Jul 12, 2024

Beijing Sun-Novo Pharmaceutical Research Co., Ltd (SHA: 688621), a biopharmaceutical company based in China, has...

Company Medical Device

Haohai Biotech’s Sodium Hyaluronate Gel Receives NMPA Approval for Aesthetic Treatments

Fineline Cube Jul 12, 2024

Shanghai Haohai Biological Technology Co. Ltd (HKG: 6826, SHA: 688366) has announced that it has...

Company

Danaher Corporation Launches Western Innovation Center in Chongqing

Fineline Cube Jul 12, 2024

Danaher Corporation (NYSE: DHR), a leading science and technology services provider based in the U.S.,...

Company Deals

Salus Biotech Partners with Xi’an Jiaotong University for Single-Cell Omics Innovation

Fineline Cube Jul 12, 2024

Salus Biotech, a Shenzhen-based biotechnology company, has entered into a strategic partnership with the Single-cell...

Company Drug

KeChow Pharma’s Keluping, First NRAS Mutant Melanoma Therapy, Hits the Market

Fineline Cube Jul 12, 2024

Shanghai-based KeChow Pharma has announced the official market launch of its groundbreaking drug, Keluping (tunlametinib),...

Company Deals

Biokin Pharmaceutical Co., Ltd Eyes Secondary Listing on HKEX, Co-Sponsored by Goldman Sachs and Others

Fineline Cube Jul 11, 2024

Sichuan Biokin Pharmaceutical Co., Ltd (SHA: 688506), a company listed on the Shanghai Stock Exchange’s...

Posts pagination

1 … 323 324 325 … 658

Recent updates

  • Huahui Health Signs $1.9 Billion Global Licensing Deal with BeOne Medicines for Trispecific Antibody HH160 Targeting PD-1, CTLA-4, and VEGF-A
  • WuXi AppTec Reports Record Q1 2026 Results with 28.8% Revenue Growth and RMB 59.77B Backlog – Chemistry Segment Leads Expansion
  • Thermo Fisher Scientific to Divest Microbiology Business to Astorg for $1.075 Billion – Strategic Portfolio Optimization
  • Novartis Secures European Commission Approval for Rhapsido (remibrutinib) in Chronic Spontaneous Urticaria – Expanding Global BTK Inhibitor Franchise
  • Eli Lilly to Acquire Ajax Therapeutics for Up to $2.3 Billion to Expand JAK Inhibitor Portfolio in Myeloproliferative Neoplasms
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Others

Huahui Health Signs $1.9 Billion Global Licensing Deal with BeOne Medicines for Trispecific Antibody HH160 Targeting PD-1, CTLA-4, and VEGF-A

Company

WuXi AppTec Reports Record Q1 2026 Results with 28.8% Revenue Growth and RMB 59.77B Backlog – Chemistry Segment Leads Expansion

Company Deals

Thermo Fisher Scientific to Divest Microbiology Business to Astorg for $1.075 Billion – Strategic Portfolio Optimization

Company Drug

Novartis Secures European Commission Approval for Rhapsido (remibrutinib) in Chronic Spontaneous Urticaria – Expanding Global BTK Inhibitor Franchise

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.